治疗复发、难治多发性骨髓瘤的新药：第56届美国血液学会年会报道  

Emerging agents for treatment of the relapsed/refractory multiple myeloma： reports from the 56th American Society of Hematology annual meeting

作　　者：周东明[1] 傅晋翔[1] 

机构地区：[1]苏州大学附属第二医院血液科,苏州215004

出　　处：《白血病．淋巴瘤》2015年第3期152-156,160,共6页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81272631）

摘　　要：复发、难治多发性骨髓瘤（RRMM）是当前临床治疗的主要难点,2014年第56届美国血液学会（ASH）年会就RRMM的最新治疗药物和方案作了详细阐述,包括药物联合应用、新型药物的临床研究,其有效性及安全性令人欣喜.文章着重介绍新型药物的作用机制、方法及毒副作用.Relapse/refractory multiple myeloma must be the main tough for the current clinical therapy,thus at the 56th American Society of Hematology annual meeting the latest treatment studies for the disease in 2014 were described in detail,including the joint application of drugs,the new drug clinical research,the safety and efficacy that could be inspiring.This chapter shows the mechanism of these new drug action,as well as the methods and side effects.

关 键 词：多发性骨髓瘤 复发 难治 美国血液学会年会 

分 类 号：R733.3[医药卫生—肿瘤]